STAT3 and ovarian carcinoma: Adding STAT3-inhibitors on ovarian cancer cells and treating them with cisplatin increases their sensitivity, leading to the hypothesis that hypoxic ovarian cancer cell-derived exosomes play an important role in the development of resistance toward this drug [69].